Rallybio Corporation shares are trading lower after JMP Securities lowered its price target from $26 to $16. The company announced Saturday data from the Phase 1b proof-of-concept study of RLYB212.
Portfolio Pulse from Benzinga Newsdesk
Rallybio Corporation shares are trading lower after JMP Securities lowered its price target from $26 to $16. The company announced data from the Phase 1b proof-of-concept study of RLYB212 on Saturday.
June 26, 2023 | 7:33 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Rallybio Corporation's stock price is trading lower after JMP Securities lowered its price target from $26 to $16, following the announcement of Phase 1b study data of RLYB212.
Rallybio Corporation's stock price is directly impacted by the news of JMP Securities lowering its price target. The announcement of Phase 1b study data of RLYB212 has led to a negative sentiment among investors, causing the stock price to trade lower.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100